Literature DB >> 18562020

Newly developed angiotensin II-infused experimental models in vascular biology.

Zhenyu Qin1.   

Abstract

Angiotensin II is a major vasoactive peptide in the renin-angiotensin system (RAS). In vitro evidence demonstrates that this peptide can modulate the function of various adhesion molecules, chemokines, cytokines and growth factors, and ultimately contributes to cell proliferation, hypertrophy and inflammation. Moreover, in vivo studies further support that angiotensin II induces several vascular alterations including sustained elevations of blood pressure, enhanced inflammatory response, increased medial thickness of the aortas, and formation of aortic dissection and aneurysms. Thus, it has been a long time that angiotensin II-induced hypertension, atherosclerosis and abdominal aortic aneurysms emerge as important experimental models with respect to vascular biology. Applications of these models to investigate the vascular diseases have dramatically improved our understanding in the pathogenesis of these diseases. However, the pathophysiology of angiotensin II in vivo remains to be determined in many other vascular diseases where angiotensin II has been implicated as the detrimental factor, at least in part due to the limit availability of animal models. Recently some new exciting experimental models based on angiotensin II infusion have been reported to replicate the human diseases, such as postmenopausal hypertension, preeclampsia, vascular remodeling, vascular aging and neovascularization. In this review, we will focus on the rationales and anticipated applications of these newly developed models, with special emphasis placed on those relevant to the vascular biology. We will also discuss the limitations of the method of chronic angiotensin II infusion and additional approaches to overcome these limitations. These experimental models will provide great opportunity for us to investigate the molecular mechanisms of angiotensin II and evaluate therapeutic approaches, particularly to finely tune the potential role of RAS activation in various vascular events using genetically engineered mice.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18562020     DOI: 10.1016/j.regpep.2008.05.002

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  9 in total

Review 1.  Molecular mechanisms of thoracic aortic dissection.

Authors:  Darrell Wu; Ying H Shen; Ludivine Russell; Joseph S Coselli; Scott A LeMaire
Journal:  J Surg Res       Date:  2013-06-29       Impact factor: 2.192

2.  Differential hypertensive protease expression in the thoracic versus abdominal aorta.

Authors:  Jean Marie Ruddy; Adam W Akerman; Denise Kimbrough; Elizabeth K Nadeau; Robert E Stroud; Rupak Mukherjee; John S Ikonomidis; Jeffrey A Jones
Journal:  J Vasc Surg       Date:  2016-12-27       Impact factor: 4.268

3.  Impaired Aortic Contractility to Uridine Adenosine Tetraphosphate in Angiotensin II-Induced Hypertensive Mice: Receptor Desensitization?

Authors:  Zhichao Zhou; Vishal R Yadav; Changyan Sun; Bunyen Teng; Jamal S Mustafa
Journal:  Am J Hypertens       Date:  2017-03-01       Impact factor: 2.689

4.  Angiotensin II type 1A receptors in vascular smooth muscle cells do not influence aortic remodeling in hypertension.

Authors:  Matthew A Sparks; Kelly K Parsons; Johannes Stegbauer; Susan B Gurley; Anuradha Vivekanandan-Giri; Christopher N Fortner; Jay Snouwaert; Eric W Raasch; Robert C Griffiths; Timothy A J Haystead; Thu H Le; Subramaniam Pennathur; Beverly Koller; Thomas M Coffman
Journal:  Hypertension       Date:  2011-01-17       Impact factor: 10.190

5.  Interleukin-10 negatively modulates extracellular signal-regulated kinases 1 and 2 in aorta from hypertensive mouse induced by angiotensin II infusion.

Authors:  Alecsander F Bressan; Gisele A Fonseca; Rita C Tostes; R Clinton Webb; Victor Vitorino Lima; Fernanda Regina Giachini
Journal:  Fundam Clin Pharmacol       Date:  2018-09-07       Impact factor: 2.748

6.  A repressor protein, Mnt, is a novel negative regulator of vascular smooth muscle cell hypertrophy by angiotensin II and neointimal hyperplasia by arterial injury.

Authors:  Takehiko Takayanagi; Akito Eguchi; Akira Takaguri; Akinari Hinoki; Allison M Bourne; Katherine J Elliott; Peter J Hurlin; Satoru Eguchi
Journal:  Atherosclerosis       Date:  2013-03-13       Impact factor: 5.162

Review 7.  Vascular metallomics: copper in the vasculature.

Authors:  Renee N Easter; Barry Lai; Erik L Ritman; Joseph A Caruso
Journal:  Vasc Med       Date:  2009-10-06       Impact factor: 3.239

8.  Zinc, copper, and blood pressure: Human population studies.

Authors:  William E Carpenter; Derek Lam; Glenn M Toney; Neal L Weintraub; Zhenyu Qin
Journal:  Med Sci Monit       Date:  2013-01-01

9.  Mixed cerebrovascular disease and the future of stroke prevention.

Authors:  Mark Fisher; Vitaly Vasilevko; David H Cribbs
Journal:  Transl Stroke Res       Date:  2012-05-04       Impact factor: 6.829

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.